2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 467

Adherence To Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) In Rheumatoid Arthritis (RA) Patients Treated In Association With a Biologic: A French Cross-Sectional Survey
Abstract Number: 1056

Adherence To Methotrexate Therapy Among Patients With Rheumatoid Arthritis In Denmark: A Registry Based Cohort Study
Abstract Number: 1465

Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
Abstract Number: 1226

Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score
Abstract Number: 773

Adioponectin-Induced p38 MAPK and AMPK Pathways In Rheumatoid Arthritis Synovial Fibroblasts Are Adiponectin Isoform Dependent
Abstract Number: 2071

Adipokines Contribute To The Inflammatory Response In Adult and Juvenile Myositis
Abstract Number: 1429

Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study
Abstract Number: 727

Adiponectin Promotes The Differentiation Of naïve T Cell To Th17 Cell and Aggravates Collagen-Induced Arthritis
Abstract Number: 2819

Administration Of a Multi-Epitope Citrullinated Peptide Attuneuates adjuvant Induced Arthritis In Rats Via Induction Of Immune Tolerance
Abstract Number: 1743

Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study
Abstract Number: 1918

Adoption Of New Electronic Medical Records May Inhibit Documentation Of Physician Quality Reporting System
Abstract Number: 1211

Adult Autoinflammatory Phenotypes Associated With Heterozygous MEFV Mutations: A Continuum of Familial Mediterranean Fever?
Abstract Number: 1954

advantages Of a Combined Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) For Hand and Feet: Does The Ramris Of The Hand Alone Underestimate Disease Activity and Progression?
Abstract Number: 1812

Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Abstract Number: 698

Adverse Events With The Use Of Radiotherapy In Patients With Connective Tissue Diseases and Cancer: A Systematic Review and Meta-Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].